Estimate 2-year and 5-year risk of kidney failure using the KFRE model. Includes CKD staging, KDIGO heatmap, nephrology referral guidance, and dialysis planning.
The Kidney Failure Risk Equation (KFRE) Calculator estimates the probability of progressing to kidney failure (requiring dialysis or transplant) within 2 and 5 years for patients with chronic kidney disease. Developed by Tangri et al. (2011, JAMA) and validated globally in over 700,000 patients across 30+ countries, the KFRE is the most widely validated CKD progression prediction tool and is now integrated into KDIGO clinical practice guidelines.
The 4-variable model uses age, sex, eGFR, and urine albumin-to-creatinine ratio (ACR) — tests routinely available in primary care — to produce individualized risk estimates. This represents a paradigm shift from the old approach of referring all patients below a fixed eGFR threshold. Instead, the KFRE identifies which CKD patients truly need specialist care and early dialysis planning, reducing unnecessary referrals by up to 30% while identifying high-risk patients earlier.
Canada, the United Kingdom, and several European countries have formally adopted the KFRE into their CKD referral pathways. This calculator also provides KDIGO staging, the CKD risk heatmap, lab assessment for CKD complications (hypocalcemia, hyperphosphatemia, acidosis), and evidence-based dialysis planning timelines based on risk thresholds.
The KFRE revolutionizes CKD management by replacing arbitrary eGFR thresholds with individualized risk predictions. It reduces unnecessary nephrology referrals while ensuring high-risk patients receive timely specialist care, dialysis planning, and transplant evaluation — improving outcomes and healthcare efficiency. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
KFRE 4-variable: 1 − baseline survival^exp(sum), where sum includes coefficients for age, sex, eGFR, and log(ACR). Baseline 2-year survival = 0.9832, 5-year = 0.9365. CKD Stage: G1 (≥90), G2 (60-89), G3a (45-59), G3b (30-44), G4 (15-29), G5 (<15).
Result: 2-year risk: 8.2%, 5-year risk: 23.5% — Nephrology referral recommended
A 55-year-old male with eGFR 35 and ACR 300 is in CKD G3b/A3 — very high risk by KDIGO heatmap. The 5-year KFRE risk exceeds 10%, meeting referral criteria. Dialysis modality education and vascular access planning should begin.
The Kidney Failure Risk Equation was developed by Navdeep Tangri and colleagues at the University of Manitoba, published in JAMA in 2011. Using data from over 8,000 CKD patients with eGFR 10-59, Tangri identified that four simple variables — age, sex, eGFR, and urine ACR — predicted kidney failure with remarkable accuracy (C-statistic 0.917).
The critical validation came in 2016 when the CKD Prognosis Consortium tested the KFRE in 31 international cohorts comprising over 700,000 patients. The model maintained excellent discrimination (C-statistic 0.90) across diverse populations, CKD etiologies, and healthcare systems — making it one of the most extensively validated prediction tools in all of nephrology.
The KFRE has fundamentally changed nephrology referral patterns in countries that have adopted it. In Manitoba (Canada), implementation reduced referrals by 30% while ensuring that the highest-risk patients were seen 6-12 months earlier. The UK Renal Association and NICE guidelines now incorporate KFRE-based referral criteria.
For patients, the KFRE provides meaningful prognostic information that supports shared decision-making. A 65-year-old woman with CKD G4 (eGFR 28) but minimal proteinuria may have only a 3% 2-year risk — very different from the same eGFR in a 50-year-old man with nephrotic-range proteinuria, whose 2-year risk may exceed 25%. This individualization helps patients understand their trajectory and make informed decisions about treatment intensity, lifestyle modifications, and advance care planning.
Several interventions are proven to slow CKD progression and reduce the risk calculated by the KFRE: RAAS inhibitors (ACEi/ARB), SGLT2 inhibitors (shown in DAPA-CKD, EMPA-KIDNEY trials to reduce kidney failure by 30-40%), finerenone (non-steroidal MRA, FIDELIO-DKD and FIGARO-DKD trials), blood pressure optimization (< 130/80 mmHg), dietary protein moderation (0.6-0.8 g/kg/day in advanced CKD), and metabolic acidosis correction with oral bicarbonate.
KDIGO and Canadian guidelines recommend nephrology referral when the 5-year KFRE risk exceeds 3-5%. Many centers use a 5% threshold for referral and a 20-40% 2-year risk threshold for dialysis access planning. The KFRE should be recalculated every 6-12 months.
Yes — the KFRE has been validated in over 30 countries (CKD-PC international consortium, 2016) including North America, Europe, Asia, and Australia. Recalibration coefficients exist for specific populations, though the 4-variable model performs well globally.
The KFRE was developed with the CKD-EPI 2009 creatinine equation. The 2021 CKD-EPI equation (without race) can also be used. Cystatin C-based eGFR may improve accuracy in populations where creatinine is unreliable (e.g., muscle wasting, liver disease).
The 4-variable model (age, sex, eGFR, ACR) has a C-statistic of 0.90-0.92 — excellent discrimination. The 8-variable model adds calcium, phosphate, albumin, and bicarbonate, improving the C-statistic to 0.91-0.94. The 4-variable model is preferred for primary care due to simpler data requirements.
The KFRE is preferred because it is more accurate. Many patients with eGFR 25-35 have low progression risk and can be safely managed in primary care, while some with eGFR 35-45 and heavy proteinuria are at high risk and need early referral.
AV fistula creation is recommended when 2-year KFRE risk exceeds 20-40%, as fistulas need 3-6 months to mature. For peritoneal dialysis catheter placement, 2-4 weeks lead time is typically sufficient. Pre-emptive transplant evaluation should begin at 2-year risk > 20%.